<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33855680</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7233</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer metastasis reviews</Title>
          <ISOAbbreviation>Cancer Metastasis Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Emerging roles for myeloid immune cells in bone metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>413</StartPage>
          <EndPage>425</EndPage>
          <MedlinePgn>413-425</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10555-021-09965-3</ELocationID>
        <Abstract>
          <AbstractText>Metastasis, especially bone metastasis, is a major cause of cancer-related deaths, which is associated with long-term pain due to skeletal-related events and poor quality of life. Tumor cells alter the bone microenvironment through aberrant activation of osteoclasts and osteoblasts which induces bone osteolysis and release of growth factors leading to cancer growth. Though this phenomenon has been well characterized, bone-targeted therapies have shown little improvement in patient survival. Recent evidence indicates a growing appreciation for the complex bone environment, in addition to bone-remodeling stromal cells, which includes an abundance of myeloid immune cells that can either protect against or contribute to the progression of the disease within the bone cavity. Additionally, myeloid cells are recruited into primary tumor sites, where they promote development of the pre-metastatic niche and also can regulate tumor progression within the tumor-bone microenvironment through a milieu of complex mechanisms and involving heterogeneous myeloid populations. In this review, we have highlighted the complex roles of myeloid immunity in bone metastasis and hope to bring attention to the potential of novel immunotherapeutic interventions for the elimination of bone metastasis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Alsamraae</LastName>
            <ForeName>Massar</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE, 68198-5900, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cook</LastName>
            <ForeName>Leah M</ForeName>
            <Initials>LM</Initials>
            <Identifier Source="ORCID">0000-0002-9996-7419</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE, 68198-5900, USA. leah.cook@unmc.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fred &amp; Pamela Buffett Cancer Center, Omaha, NE, USA. leah.cook@unmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Cancer Metastasis Rev</MedlineTA>
        <NlmUniqueID>8605731</NlmUniqueID>
        <ISSNLinking>0167-7659</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bone</Keyword>
        <Keyword MajorTopicYN="Y">Immunity</Keyword>
        <Keyword MajorTopicYN="Y">Metastasis</Keyword>
        <Keyword MajorTopicYN="Y">Myeloid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>7</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33855680</ArticleId>
        <ArticleId IdType="doi">10.1007/s10555-021-09965-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s10555-021-09965-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Valastyan, S., &amp; Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147, 275–292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22000009</ArticleId>
            <ArticleId IdType="pmc">3261217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie, P. (1997). Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta. Revue du Rhumatisme (English Ed.), 64, 44–53.</Citation>
        </Reference>
        <Reference>
          <Citation>Linkhart, T. A., Mohan, S., &amp; Baylink, D. J. (1996). Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone, 19, 1S–12S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8830994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribatti, D., Mangialardi, G., &amp; Vacca, A. (2006). Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clinical and Experimental Medicine, 6, 145–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17191105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langley, R. R., &amp; Fidler, I. J. (2011). The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128, 2527–2535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21365651</ArticleId>
            <ArticleId IdType="pmc">3075088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boskey, A. L., &amp; Posner, A. S. (1984). Bone structure, composition, and mineralization. The Orthopedic Clinics of North America, 15, 597–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6387574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitaura, H., et al. (2020). Osteocyte-related cytokines regulate osteoclast formation and bone resorption. International Journal of Molecular Sciences, 21.</Citation>
        </Reference>
        <Reference>
          <Citation>Udagawa, N., Koide, M., Nakamura, M., Nakamichi, Y., Yamashita, T., Uehara, S., Kobayashi, Y., Furuya, Y., Yasuda, H., Fukuda, C., &amp; Tsuda, E. (2021). Osteoclast differentiation by RANKL and OPG signaling pathways. Journal of Bone and Mineral Metabolism, 39, 19–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33079279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald, M. M., &amp; Delgado-Calle, J. (2017). Sclerostin: an emerging target for the treatment of cancer-induced bone disease. Current Osteoporosis Reports, 15, 532–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28956252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parfitt, A. M. (1976). The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism, 25, 909–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">181659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua, R., Zhang, J., Riquelme, M. A., &amp; Jiang, J. X. (2021). Connexin gap junctions and hemichannels link oxidative stress to skeletal physiology and pathology. Current Osteoporosis Reports, 19, 66–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33403446</ArticleId>
            <ArticleId IdType="pmc">8174533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karkache, I. Y., Damodaran, J. R., Molstad, D. H. H., &amp; Bradley, E. W. (2021). Serine/threonine phosphatases in osteoclastogenesis and bone resorption. Gene, 771, 145362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33338510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowe, P., Koller, A., &amp; Sharma, S. (2021). Physiology, bone remodeling. In StatPearls. Treasure Island (FL).</Citation>
        </Reference>
        <Reference>
          <Citation>Cook, L. M., Shay, G., Araujo, A., &amp; Lynch, C. C. (2014). Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases. Cancer Metastasis Reviews, 33, 511–525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24414228</ArticleId>
            <ArticleId IdType="pmc">4096318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cook, L. M., Araujo, A., Pow-Sang, J. M., Budzevich, M. M., Basanta, D., &amp; Lynch, C. C. (2016). Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Scientific Reports, 6, 29384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27411810</ArticleId>
            <ArticleId IdType="pmc">4944130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito, M., Guise, T., &amp; Kang, Y. (2018). The biology of bone metastasis. Cold Spring Harbor Perspectives in Medicine, 8.</Citation>
        </Reference>
        <Reference>
          <Citation>Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., &amp; Costa, L. (2020). Bone metastases. Nature Reviews. Disease Primers, 6, 83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33060614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin, S. C., Yu-Lee, L. Y., &amp; Lin, S. H. (2018). Osteoblastic factors in prostate cancer bone metastasis. Current Osteoporosis Reports, 16, 642–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30203251</ArticleId>
            <ArticleId IdType="pmc">6234057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda, H. (2019). The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients. Nihon Yakurigaku Zasshi, 153, 11–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30643086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frieling, J. S., Basanta, D., &amp; Lynch, C. C. (2015). Current and emerging therapies for bone metastatic castration-resistant prostate cancer. Cancer Control, 22, 109–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25504285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dionisio, M. R., et al. (2019). Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss. British Journal of Clinical Pharmacology, 85, 1114–1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30601585</ArticleId>
            <ArticleId IdType="pmc">6533479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihle, C. L., &amp; Owens, P. (2020). Integrating the immune microenvironment of prostate cancer induced bone disease. Molecular Carcinogenesis, 59, 822–829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32233011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu, C., Hua, Q., &amp; Zheng, L. (2020). Generation of myeloid cells in cancer: the spleen matters. Frontiers in Immunology, 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, E., Xu, H., Wang, L., Kryczek, I., Wu, K., Hu, Y., Wang, G., &amp; Zou, W. (2012). Bone marrow and the control of immunity. Cellular &amp; Molecular Immunology, 9, 11–19.</Citation>
        </Reference>
        <Reference>
          <Citation>Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., &amp; Breckpot, K. (2018). Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression. Frontiers in Immunology, 9, 1977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30233579</ArticleId>
            <ArticleId IdType="pmc">6127274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamarin, D., et al. (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine, 6, 226ra232-226ra232.</Citation>
        </Reference>
        <Reference>
          <Citation>Serbina, N. V., Jia, T., Hohl, T. M., &amp; Pamer, E. G. (2008). Monocyte-mediated defense against microbial pathogens. Annual Review of Immunology, 26, 421–452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18303997</ArticleId>
            <ArticleId IdType="pmc">2921669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kylmaoja, E., et al. (2018). Peripheral blood monocytes show increased osteoclast differentiation potential compared to bone marrow monocytes. Heliyon, 4, e00780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30225379</ArticleId>
            <ArticleId IdType="pmc">6138956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara, N., &amp; Kobayashi, K. (2005). Macrophages in inflammation. Current Drug Targets. Inflammation and Allergy, 4, 281–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16101534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart, P. H., &amp; Whitty, G. A. (1988). Piccoli, D.S. &amp; Hamilton, J.A. Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-1 activity. Journal of Immunology, 141, 1516–1521.</Citation>
        </Reference>
        <Reference>
          <Citation>Randow, F., et al. (1997). In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. Journal of Immunology, 158, 2911–2918.</Citation>
        </Reference>
        <Reference>
          <Citation>Bundschuh, D. S., et al. (1997). Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. Journal of Immunology, 158, 2862–2871.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassetta, L., &amp; Pollard, J. W. (2018). Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery, 17, 887–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30361552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon, S. (2003). Alternative activation of macrophages. Nature Reviews. Immunology, 3, 23–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12511873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu, J., Zhi, Q., P. Zhou, B., Tao, M., Liu, J., &amp; Li, W. (2016). The role of tumor associated macrophages in the tumor nicroenvironment: mechanism and functions. Anti-Cancer Agents in Medicinal Chemistry, 16, 1133–1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27198986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogers, T. L., &amp; Holen, I. (2011). Tumour macrophages as potential targets of bisphosphonates. Journal of Translational Medicine, 9, 177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22005011</ArticleId>
            <ArticleId IdType="pmc">3215187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchini, R., Karagiannis, S. N., Jordakieva, G., &amp; Jensen-Jarolim, E. (2020). The Role of IgG4 in the fine tuning of tolerance in IgE-mediated allergy and cancer. International Journal of Molecular Sciences, 21.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., Roodman, G. D., &amp; Zhang, J. (2007). Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Research, 67, 3646–3653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17440076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loberg, R. D., Day, L. S. L., Harwood, J., Ying, C., St. John, L. N., Giles, R., Neeley, C. K., &amp; Pienta, K. J. (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia, 8, 578–586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16867220</ArticleId>
            <ArticleId IdType="pmc">1601934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Craig, M. J., &amp; Loberg, R. D. (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Reviews, 25, 611–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17160712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizutani, K., Sud, S., McGregor, N. A., Martinovski, G., Rice, B. T., Craig, M. J., Varsos, Z. S., Roca, H., &amp; Pienta, K. J. (2009). The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia, 11, 1235–1242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19881959</ArticleId>
            <ArticleId IdType="pmc">2767225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiraoka, K., Zenmyo, M., Watari, K., Iguchi, H., Fotovati, A., Kimura, Y. N., Hosoi, F., Shoda, T., Nagata, K., Osada, H., Ono, M., &amp; Kuwano, M. (2008). Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science, 99, 1595–1602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18754872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roelofs, A. J., Thompson, K., Ebetino, F. H., Rogers, M. J., &amp; Coxon, F. P. (2010). Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Current Pharmaceutical Design, 16, 2950–2960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20722616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panni, R. Z., Linehan, D. C., &amp; DeNardo, D. G. (2013). Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy, 5, 1075–1087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24088077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur, S., et al. (2017). Role of bone marrow macrophages in controlling homeostasis and repair in bone and bone marrow niches. In Seminars in cell &amp; developmental biology (Vol. 61, pp. 12–21). Elsevier.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones, J. D., Sinder, B. P., Paige, D., Soki, F. N., Koh, A. J., Thiele, S., Shiozawa, Y., Hofbauer, L. C., Daignault, S., Roca, H., &amp; McCauley, L. K. (2019). Trabectedin reduces skeletal prostate cancer tumor size in association with effects on M2 macrophages and efferocytosis. Neoplasia, 21, 172–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30591422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang, P., Gao, W., Ma, T., Wang, R., Piao, Y., Dong, X., Wang, P., Zhang, X., Liu, Y., Su, W., Xiang, R., Zhang, J., &amp; Li, N. (2019). CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages. Theranostics, 9, 2950–2966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31244935</ArticleId>
            <ArticleId IdType="pmc">6568184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welm, A. L., Sneddon, J. B., Taylor, C., Nuyten, D. S. A., van de Vijver, M. J., Hasegawa, B. H., &amp; Bishop, J. M. (2007). The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences, 104, 7570–7575.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel, S. A., Ramkissoon, S. H., Bryan, M., Pliner, L. F., Dontu, G., Patel, P. S., Amiri, S., Pine, S. R., &amp; Rameshwar, P. (2012). Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Scientific Reports, 2, 906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23205268</ArticleId>
            <ArticleId IdType="pmc">3510468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker, N. D., Elias, M., Guiro, K., Bhatia, R., Greco, S. J., Bryan, M., Gergues, M., Sandiford, O. A., Ponzio, N. M., Leibovich, S. J., &amp; Rameshwar, P. (2019). Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma. Cell Death &amp; Disease, 10, 59.</Citation>
        </Reference>
        <Reference>
          <Citation>Walker, N. D., et al. (2019). Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma. Cell Death &amp; Disease, 10, 1–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Raggi, C., Mousa, H. S., Correnti, M., Sica, A., &amp; Invernizzi, P. (2016). Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene, 35, 671–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25961921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noy, R., &amp; Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41, 49–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25035953</ArticleId>
            <ArticleId IdType="pmc">4137410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao, X.-J., et al. (2019). Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. Acta Pharmacologica Sinica, 40, 1343–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31296953</ArticleId>
            <ArticleId IdType="pmc">6786412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinman, R. M. (2006). Linking innate to adaptive immunity through dendritic cells. Novartis Foundation Symposium, 279, 101–109; discussion 109-113, 216-109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17278389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bashyam, H. (2007). Ralph Steinman: dendritic cells bring home the Lasker. The Journal of Experimental Medicine, 204, 2245–2248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17908939</ArticleId>
            <ArticleId IdType="pmc">2118467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, E., Tussiwand, R., &amp; Yona, S. (2014). Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nature Reviews. Immunology, 14, 571–578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25033907</ArticleId>
            <ArticleId IdType="pmc">4638219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segerer, S., Heller, F., Lindenmeyer, M. T., Schmid, H., Cohen, C. D., Draganovici, D., Mandelbaum, J., Nelson, P. J., Gröne, H. J., Gröne, E. F., Figel, A. M., Nössner, E., &amp; Schlöndorff, D. (2008). Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney International, 74, 37–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18368027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ardavin, C. (2004). Amigorena, S. &amp; Reis e Sousa, C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity, 20, 17–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14738761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambrecht, B. N., Salomon, B., Klatzmann, D., &amp; Pauwels, R. A. (1998). Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. Journal of Immunology, 160, 4090–4097.</Citation>
        </Reference>
        <Reference>
          <Citation>Tucci, M., Stucci, S., Strippoli, S., Dammacco, F., &amp; Silvestris, F. (2011). Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist, 16, 1040–1048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21659611</ArticleId>
            <ArticleId IdType="pmc">3228131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, B., Dong, Y., Tian, Z., Chen, Y., &amp; Dong, S. (2020). The role of dendritic cells derived osteoclasts in bone destruction diseases. Genes &amp; Diseases.</Citation>
        </Reference>
        <Reference>
          <Citation>Veglia, F., &amp; Gabrilovich, D. I. (2017). Dendritic cells in cancer: the role revisited. Current Opinion in Immunology, 45, 43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28192720</ArticleId>
            <ArticleId IdType="pmc">5449252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawant, A., Hensel, J. A., Chanda, D., Harris, B. A., Siegal, G. P., Maheshwari, A., &amp; Ponnazhagan, S. (2012). Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology, 189, 4258–4265.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin, A., &amp; Lore, K. (2017). Granulocytes: new members of the antigen-presenting cell family. Frontiers in Immunology, 8, 1781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29321780</ArticleId>
            <ArticleId IdType="pmc">5732227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geering, B., Stoeckle, C., Conus, S., &amp; Simon, H. U. (2013). Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends in Immunology, 34, 398–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23665135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosales, C., Lowell, C. A., Schnoor, M., &amp; Uribe-Querol, E. (2017). Neutrophils: their role in innate and adaptive immunity 2017. Journal of Immunology Research, 2017, 9748345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29238732</ArticleId>
            <ArticleId IdType="pmc">5697120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D., &amp; Zychlinsky, A. (2012). Neutrophil function: from mechanisms to disease. Annual Review of Immunology, 30, 459–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22224774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang, W., &amp; Ferrara, N. (2016). The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunology Research, 4, 83–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26839309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S., &amp; Weiss, S. (2010). Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. The Journal of Clinical Investigation, 120, 1151–1164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20237412</ArticleId>
            <ArticleId IdType="pmc">2846036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, Y., O'Leary, C. E., Wang, L. C. S., Bhatti, T. R., Dai, N., Kapoor, V., Liu, P., Mei, J., Guo, L., Oliver, P. M., Albelda, S. M., &amp; Worthen, G. S. (2016). CD11b+ Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology, 5, e1061175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26942073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., &amp; Albelda, S. M. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-β:“N1” versus “N2” TAN. Cancer cell, 16, 183–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19732719</ArticleId>
            <ArticleId IdType="pmc">2754404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andzinski, L., Kasnitz, N., Stahnke, S., Wu, C. F., Gereke, M., von Köckritz-Blickwede, M., Schilling, B., Brandau, S., Weiss, S., &amp; Jablonska, J. (2016). Type I IFN s induce anti-tumor polarization of tumor associated neutrophils in mice and human. International Journal of Cancer, 138, 1982–1993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26619320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan, B., Wei, J. J., Yuan, Y., Sun, R., Li, D., Luo, J., Liao, S. J., Zhou, Y. H., Shu, Y., Wang, Q., Zhang, G. M., &amp; Feng, Z. H. (2013). IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation. Journal of Immunology, 190, 5882–5893.</Citation>
        </Reference>
        <Reference>
          <Citation>Casbon, A.-J., Reynaud, D., Park, C., Khuc, E., Gan, D. D., Schepers, K., Passegué, E., &amp; Werb, Z. (2015). Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proceedings of the National Academy of Sciences, 112, E566–E575.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim, M., Song, C., Jeong, I. G., Choi, S. K., Park, M., Shim, M., Kim, Y. S., You, D., Hong, J. H., Kim, C. S., &amp; Ahn, H. (2018). Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study. BMC Cancer, 18, 271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29523103</ArticleId>
            <ArticleId IdType="pmc">5845289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costanzo-Garvey, D. L., Keeley, T., Case, A. J., Watson, G. F., Alsamraae M., Yu Y., Su, K., Heim, C. E., Kielian T., Morrissey, C., Frieling, J. S., &amp; Cook, L. M. (2020). Neutrophils are mediators of metastatic prostate cancer progression in bone. Cancer Immunology, Immunotherapy, 1–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Gollnick, S. O., Evans, S. S., Baumann, H., Owczarczak, B., Maier, P., Vaughan, L., Wang, W. C., Unger, E., &amp; Henderson, B. W. (2003). Role of cytokines in photodynamic therapy-induced local and systemic inflammation. British Journal of Cancer, 88, 1772–1779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12771994</ArticleId>
            <ArticleId IdType="pmc">2377133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu, D., Dong, X., Zhao, Q., Gu, J., &amp; Wang, Z. (2017). Photosensitization priming of tumor microenvironments improves delivery of nanotherapeutics via neutrophil infiltration. Advanced Materials, 29.</Citation>
        </Reference>
        <Reference>
          <Citation>Kang, T., Zhu, Q., Wei, D., Feng, J., Yao, J., Jiang, T., Song, Q., Wei, X., Chen, H., Gao, X., &amp; Chen, J. (2017). Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano, 11, 1397–1411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28075552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keeley, T., Costanzo-Garvey, D. L., &amp; Cook, L. M. (2019). Unmasking the many faces of tumor-associated neutrophils and macrophages: considerations for targeting innate immune cells in cancer. Trends Cancer, 5, 789–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31813456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budhwar, S., Verma, P., Verma, R., Rai, S., &amp; Singh, K. (2018). The yin and yang of myeloid derived suppressor cells. Frontiers in Immunology, 9, 2776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30555467</ArticleId>
            <ArticleId IdType="pmc">6280921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meirow, Y., Kanterman, J., &amp; Baniyash, M. (2015). Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Frontiers in Immunology, 6, 523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26528286</ArticleId>
            <ArticleId IdType="pmc">4601280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raber, P., Ochoa, A. C., &amp; Rodríguez, P. C. (2012). Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunological Investigations, 41, 614–634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23017138</ArticleId>
            <ArticleId IdType="pmc">3519282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdan, C. (2001). Nitric oxide and the immune response. Nature Immunology, 2, 907–916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11577346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker, K. H., Beury, D. W., &amp; Ostrand-Rosenberg, S. (2015). Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. In Advances in cancer research (Vol. 128, pp. 95–139). Elsevier.</Citation>
        </Reference>
        <Reference>
          <Citation>Umansky, V., Blattner, C., Gebhardt, C., &amp; Utikal, J. (2016). The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel), 4.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, J., Sun, H. W., Yang, Y. Y., Chen, H. T., Yu, X. J., Wu, W. C., Xu, Y. T., Jin, L. L., Wu, X. J., Xu, J., &amp; Zheng, L. (2021). Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduction and Targeted Therapy, 6, 4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33414378</ArticleId>
            <ArticleId IdType="pmc">7791142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales, J. K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H. D., &amp; Manjili, M. H. (2009). Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 58, 941–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18979098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawant, A., Deshane, J., Jules, J., Lee, C. M., Harris, B. A., Feng, X., &amp; Ponnazhagan, S. (2013). Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research, 73, 672–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23243021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuznik, A., Pazdzierniok-Holewa, A., Jewula, P., &amp; Kuznik, N. (2020). Bisphosphonates-much more than only drugs for bone diseases. European Journal of Pharmacology, 866, 172773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31705903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., &amp; Colombo, M. P. (2007). Amino-biphosphonate–mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67, 11438–11446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18056472</ArticleId>
            <ArticleId IdType="pmc">2646404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg, S., &amp; Fenselau, C. (2018). Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. Journal of Immunology, 200, 422–431.</Citation>
        </Reference>
        <Reference>
          <Citation>Condamine, T., Ramachandran, I., Youn, J. I., &amp; Gabrilovich, D. I. (2015). Regulation of tumor metastasis by myeloid-derived suppressor cells. Annual Review of Medicine, 66, 97–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25341012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., Viatour, P., Lavilla-Alonso, S., Polo, A. T., Tcyganov, E. N., Mulligan Jr., C., Nam, B., Bennett, J., Masters, G., Guarino, M., Kumar, A., Nefedova, Y., Vonderheide, R. H., Languino, L. R., Abrams, S. I., &amp; Gabrilovich, D. I. (2019). Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Journal of Experimental Medicine, 216, 2150–2169.</Citation>
        </Reference>
        <Reference>
          <Citation>Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., &amp; Ostrand-Rosenberg, S. (2007). Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Journal of Immunology, 179, 977–983.</Citation>
        </Reference>
        <Reference>
          <Citation>Mulero, I., Sepulcre, M. P., Meseguer, J., García-Ayala, A., &amp; Mulero, V. (2007). Histamine is stored in mast cells of most evolutionarily advanced fish and regulates the fish inflammatory response. Proceedings of the National Academy of Sciences, 104, 19434–19439.</Citation>
        </Reference>
        <Reference>
          <Citation>Marone, G., Galli, S. J., &amp; Kitamura, Y. (2002). Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends in Immunology, 23, 425–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirshenbaum, A. S., et al. (1999). Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood, The Journal of the American Society of Hematology, 94, 2333–2342.</Citation>
        </Reference>
        <Reference>
          <Citation>Sammarco, G., Varricchi, G., Ferraro, V., Ammendola, M., de Fazio, M., Altomare, D. F., Luposella, M., Maltese, L., Currò, G., Marone, G., Ranieri, G., &amp; Memeo, R. (2019). Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. International Journal of Molecular Sciences, 20, 2106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">6540185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiménez-Andrade, G. Y., Ibarra-Sánchez, A., González, D., Lamas, M., &amp; González-Espinosa, C. (2013). Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism. Journal of Hematology &amp; Oncology, 6, 1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Siiskonen, H., Poukka, M., Bykachev, A., Tyynelä-Korhonen, K., Sironen, R., Pasonen-Seppänen, S., &amp; Harvima, I. T. (2015). Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma. Melanoma Research, 25, 479–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26317168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, A., Herken, R., Roncali, L., &amp; Dammacco, F. (1999). Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer, 79, 451–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10027312</ArticleId>
            <ArticleId IdType="pmc">2362443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyzoukaki, R., Tsirakis, G., Pappa, C. A., Devetzoglou, M., Tzardi, M., &amp; Alexandrakis, M. G. (2015). The impact of mast cell density on the progression of bone disease in multiple myeloma patients. International Archives of Allergy and Immunology, 168, 263–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26894886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leporini, C., Ammendola, M., Marech, I., Sammarco, G., Sacco, R., Gadaleta, C. D., Oakley, C., Russo, E., de Sarro, G., &amp; Ranieri, G. (2015). Targeting mast cells in gastric cancer with special reference to bone metastases. World journal of gastroenterology: WJG, 21, 10493–10501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26457010</ArticleId>
            <ArticleId IdType="pmc">4588072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammendola, M., Marech, I., Sammarco, G., Zuccalà, V., Luposella, M., Zizzo, N., Patruno, R., Crovace, A., Ruggieri, E., Zito, A., Gadaleta, C., Sacco, R., &amp; Ranieri, G. (2015). Infiltrating mast cells correlate with angiogenesis in bone metastases from gastric cancer patients. International Journal of Molecular Sciences, 16, 3237–3250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25648323</ArticleId>
            <ArticleId IdType="pmc">4346892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushansky, K. Thrombopoietin: the primary regulator of platelet production [see comments]. (1995).</Citation>
        </Reference>
        <Reference>
          <Citation>Niswander, L. M., Fegan, K. H., Kingsley, P. D., McGrath, K. E., &amp; Palis, J. (2014). SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury. Blood, 124, 277–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24735964</ArticleId>
            <ArticleId IdType="pmc">4093683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kacena, M. A., Nelson, T., Clough, M. E., Lee, S. K., Lorenzo, J. A., Gundberg, C. M., &amp; Horowitz, M. C. (2006). Megakaryocyte-mediated inhibition of osteoclast development. Bone, 39, 991–999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16782418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, X., Koh, A. J., Wang, Z., Soki, F. N., Park, S. I., Pienta, K. J., &amp; McCauley, L. K. (2011). Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. Journal of Bone and Mineral Research, 26, 125–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20684002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson, W., et al. (2017). Role of megakaryocytes in breast cancer metastasis to bone. Cancer Research, 77, 1942–1954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28202531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leblanc, R., &amp; Peyruchaud, O. (2016). Metastasis: new functional implications of platelets and megakaryocytes. Blood, The Journal of the American Society of Hematology, 128, 24–31.</Citation>
        </Reference>
        <Reference>
          <Citation>English, D., Garcia, J. G., &amp; Brindley, D. (2001). Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovascular Research, 49, 588–599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11166272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desgrosellier, J. S., &amp; Cheresh, D. A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nature Reviews. Cancer, 10, 9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20029421</ArticleId>
            <ArticleId IdType="pmc">4383089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamidi, H., &amp; Ivaska, J. (2018). Every step of the way: integrins in cancer progression and metastasis. Nature Reviews. Cancer, 18, 533–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30002479</ArticleId>
            <ArticleId IdType="pmc">6629548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakewell, S. J., Nestor, P., Prasad, S., Tomasson, M. H., Dowland, N., Mehrotra, M., Scarborough, R., Kanter, J., Abe, K., Phillips, D., &amp; Weilbaecher, K. N. (2003). Platelet and osteoclast β3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences, 100, 14205–14210.</Citation>
        </Reference>
        <Reference>
          <Citation>Uluçkan, Ö., Eagleton, M. C., Floyd, D. H., Morgan, E. A., Hirbe, A. C., Kramer, M., Dowland, N., Prior, J. L., Piwnica-Worms, D., Jeong, S. S., Chen, R., &amp; Weilbaecher, K. (2008). APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry, 104, 1311–1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18260128</ArticleId>
            <ArticleId IdType="pmc">2763643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boucharaba, A., Serre, C. M., Grès, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., Clézardin, P., &amp; Peyruchaud, O. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114, 1714–1725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15599396</ArticleId>
            <ArticleId IdType="pmc">535068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leblanc, R., &amp; Peyruchaud, O. (2015). New insights into the autotaxin/LPA axis in cancer development and metastasis. Experimental Cell Research, 333, 183–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25460336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leblanc, R., Houssin, A., &amp; Peyruchaud, O. (2018). Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. British Journal of Pharmacology, 175, 3100–3110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29777586</ArticleId>
            <ArticleId IdType="pmc">6031885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nontumoral, A. Interaction of platelet-derived autotaxin with tumor integrin aVb3 controls metastasis of breast cancer cells to bone. (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Benesch, M. G., et al. (2014). Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. The FASEB Journal, 28, 2655–2666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24599971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macedo, F., et al. (2017). Bone Metastases: An Overview. Oncol Rev, 11, 321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28584570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren, G., Esposito, M., &amp; Kang, Y. (2015). Bone metastasis and the metastatic niche. Journal of Molecular Medicine (Berlin, Germany), 93, 1203–1212.</Citation>
        </Reference>
        <Reference>
          <Citation>Florencio-Silva, R., Sasso, G. R., Sasso-Cerri, E., Simoes, M. J., &amp; Cerri, P. S. (2015). Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. BioMed Research International, 2015, 421746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26247020</ArticleId>
            <ArticleId IdType="pmc">4515490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schafer, R., et al. (2019). Quantitation of progenitor cell populations and growth factors after bone marrow aspirate concentration. Journal of Translational Medicine, 17, 115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30961655</ArticleId>
            <ArticleId IdType="pmc">6454687</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
